EULAR disease activity

Adalimumab

n (%)

Etarnercept

n (%)

Rituximab

n (%)

0 Months n %

HDA > 5.1

MDA > 3.2 < 5.1

LDA > 2.6 < 3.2

Remission < 2.6

41

34 (82.9)

7 (17.1)

29

23 (79.3)

6 (20.7)

50

44 (88)

5 (10)

1 (2)

6 Months n %

HDA > 5.1

MDA > 3.2 < 5.1

LDA > 2.6 < 3.2

Remission < 2.6

27

7 (25.9)

7 (25.9)

5 (18.5)

8 (29.6)

21

3 (14.3)

8 (38.1)

7 (33.3)

3 (14.3)

35

16 (45.7)

11 (31.4)

3 (8.6)

5 (14.3)

12 Months n%

HDA > 5.1

MDA > 3.2 < 5.1

LDA > 2.6 < 3.2

Remission < 2.6

21

8 (38.1)

7 (33.3)

2 (9.5)

4 (19)

15

2 (13.3%)

6 (40%)

2 (13.3%)

5 (33.3%)

25

7 (28)

9 (36)

5 (20)

4 (16)